The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
|Videos|October 11, 2016
EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS: Case 1
EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS
Advertisement
Riess case 1:
A 44-year-old female with relapsed stage IV adenocarcinoma.
- This is a 44-year-old female diagnosed with stage IV adenocarcinoma
- Tissue-based mutation testing showed an EGFR mutation with exon 19 deletion
- She was subsequently treated with afatinib
- After 11 months she became mildly symptomatic with small, nonspecific pulmonary nodules
- Follow up CT scan showed growth of the primary lesion
- The patient reported worsening of her cough
- Cell-free DNA testing was ordered and was negative for both the EGFR driver mutation and for T790M
- Subsequent tissue biopsy showed the presence of T790M
- The patient was switched to osimertinib and continues to respond well to therapy with minimal toxicity
Advertisement
Related to this article
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.
US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
SOT106 Receives New FDA FTD and ODD in Sarcoma
2
Iberdomide Doubles MRD-Negative CR Rate in Phase 3 EXCALIBER-RRMM Trial
3
IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions
4
Trispecifics: A New Strategy to Prevent Antigen Escape
5